Quantcast

Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
July 31, 2014, 08:14:05 PM

Login with username, password and session length


Members
  • Total Members: 23101
  • Latest: whale.
Stats
  • Total Posts: 632587
  • Total Topics: 47912
  • Online Today: 287
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Could this be the holy grail ?  (Read 160800 times)

0 Members and 1 Guest are viewing this topic.

Offline veritas

  • Member
  • Posts: 1,408
Re: Could this be the holy grail ?
« Reply #600 on: June 28, 2010, 04:53:33 AM »
I guess if this were approved by the FDA for other viruses, it could then be used "off label" for HIV?

I don't see any reason why not.

v

Offline stargate12

  • Member
  • Posts: 30
Re: Could this be the holy grail ?
« Reply #601 on: July 07, 2010, 12:23:11 PM »
 Peregrine's stock price was $2.15 then and $1.75 now. A 18.6% drop.

One of the most basic rules of investing is to never try and catch a falling knife. Very low percentage chance of success. Never try to catch a falling knife - ever.

What is the explanation of this drop ?

Offline veritas

  • Member
  • Posts: 1,408
Re: Could this be the holy grail ?
« Reply #602 on: July 08, 2010, 04:37:00 AM »

stargate12,

This thread is NOT a stock blog. If an investor cannot figure out why a stock is moving in a certain way, they shouldn't be in the stock market.  I said here before, you invest at your own risk.

Please, start your own thread, if you want to discuss the stock market. This thread is dedicated to anti-ps science only.

v

Offline veritas

  • Member
  • Posts: 1,408
Re: Could this be the holy grail ?
« Reply #603 on: July 14, 2010, 09:37:05 AM »

new phase II B trial for Non-small cell lung cancer (one of the most difficult cancers to treat) to commence:

http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=487983

Bavi has difficult cancers in the crosshairs!

Now when are we going to hear more from CHAVI? That's the question.

v

Offline veritas

  • Member
  • Posts: 1,408
Re: Could this be the holy grail ?
« Reply #604 on: September 07, 2010, 09:49:38 AM »

The patent that  I have been waiting to see has been granted  excerpts:

"In both cases, the compositions, methods and uses inhibit one or more steps or stages necessary for a productive or ongoing viral infection, including inhibiting viral entry. Preferably, the compositions, methods and uses inhibit viral replication and/or spread, such as inhibiting one or more steps of viral transcription, translation, assembly, packaging and/or egress within or from an infected host cell, such as a mammalian or human cell. The invention therefore preferably limits or substantially confines viral infections to initially infected cells and cell populations, thus substantially inhibiting or preventing the subsequent or ongoing infection of additional host cells or tissues."

"As the invention inhibits one or more steps or stages necessary for productive or ongoing infection common to all viruses, the anti-viral methods and uses of the invention are suitable for treating all viruses, both enveloped and non-enveloped viruses, including those that infect plants, animals, vertebrates, mammals and human patients. The invention is suitable for treating all viruses that infect vertebrates, as listed herein in Table H, particularly humans, and particularly viruses that are pathogenic in animals and humans. The viral infections and associated and resultant diseases that can be treated by the invention include those viruses and diseases set forth in Table J, as exemplified by treating CMV, RSV, arenavirus and HIV infections, and the diseases hepatitis, influenza, pneumonia, Lassa fever and AIDS. "

If you read this patent (it's long), remember 3g4 is in clinical trials for  combo hepc/hiv.

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=7,790,159.PN.&OS=PN/7,790,159

It's Happening!


v

Offline Inchlingblue

  • Member
  • Posts: 3,119
  • Chad Ochocinco PETA Ad
Re: Could this be the holy grail ?
« Reply #605 on: September 07, 2010, 11:00:06 AM »
Wow, that's exciting.

Is this patent for several monoclonal antibodies?

Offline veritas

  • Member
  • Posts: 1,408
Re: Could this be the holy grail ?
« Reply #606 on: September 07, 2010, 02:07:27 PM »

Inch,

The patent focuses on two antibodies (3g4 and 9d2) both are anti-ps antibodies with the 3g4 antibody seemingly the preferred. Remember that these antibodies are the "guidance system that directs the payload". Both of these antibodies can be armed with almost any nrti, nnrti and pi to do the job. The fact that the payload is target- directed, substantially, lowers the risk of AEs.

Of course these antibodies can be directed to cancers also (ie: KS, lung etc) with a different payload. Currently in phase 2 clinical trials for cancer with the 3g4 antibody.

v

Offline veritas

  • Member
  • Posts: 1,408
Re: Could this be the holy grail ?
« Reply #607 on: September 10, 2010, 09:14:05 AM »


Steve King, CEO of Peregrine Pharm., answers a question concerning Bavi and hiv therapeutic, hinting at the data they are seeing in the hep/c/ Hiv trial:

"Any thought on possibly moving forward with a drug cocktail in HIV as well? Obviously what the data shows but –

Steve King

Yeah, I think we'll let the data drive that discussion. But I think absolutely. Again Bavi is really designed if you will for combination therapy with direct antivirals in the infectious disease area."

v

Offline Inchlingblue

  • Member
  • Posts: 3,119
  • Chad Ochocinco PETA Ad
Re: Could this be the holy grail ?
« Reply #608 on: September 11, 2010, 01:48:53 AM »

Steve King, CEO of Peregrine Pharm., answers a question concerning Bavi and hiv therapeutic, hinting at the data they are seeing in the hep/c/ Hiv trial:

"Any thought on possibly moving forward with a drug cocktail in HIV as well? Obviously what the data shows but –

Steve King

Yeah, I think we'll let the data drive that discussion. But I think absolutely. Again Bavi is really designed if you will for combination therapy with direct antivirals in the infectious disease area."

v


So he is saying that it's designed to be used alongside ARVs?

Offline veritas

  • Member
  • Posts: 1,408
Re: Could this be the holy grail ?
« Reply #609 on: September 11, 2010, 09:54:58 AM »

Inch,

Bavi is the guided missle, ARVs are the payload (perhaps antibodies also, as being studied by CHAVI). The ARVs can be attached to bavi (see posts above) to enhance the effectiveness of the therapy and diminish AEs. I know the patent is a long read, but there is a lot of neat information contained within the patent that explains the MOA.

v

Offline veritas

  • Member
  • Posts: 1,408
Re: Could this be the holy grail ?
« Reply #610 on: October 08, 2010, 09:18:52 AM »
Defense threat initiative conference in Nov:

 http://cbdstconf2010.sainc.com
Agenda: http://cbdstconf2010.sainc.com/conference_agenda/tentative_agenda.aspx
11-16-10 6-8pm, Track: Host-Directed Therapeutics & Immunomodulation
Poster #T02-003, “Targeting of Anionic Phospholipids Exposed on Infected Cells & Virions: Potential Broad-Spectrum Antiviral Therapy”
Kara Corbin-Lickfett, Peregrine Pharmaceuticals

v

Offline veritas

  • Member
  • Posts: 1,408
Re: Could this be the holy grail ?
« Reply #611 on: October 08, 2010, 06:00:04 PM »

This power point presentation was showcased at the International AIDS vaccine conference in Atlanta during sept. Dr. Gary Nabel of CHAVI was the presenter. The same antibodies used for a preventative vaccine can also be used as a therapeutic. The pathway is becoming focused. Is there light at the end of the tunnel? It seems so.

http://nationalpress.org/images/uploads/programs/ATLj2j_Nabel.ppt

v

Offline ElZorro

  • Member
  • Posts: 535
Re: Could this be the holy grail ?
« Reply #612 on: October 08, 2010, 10:47:03 PM »
Pretty slides, V, but what do they mean?  :-\

Offline tednlou2

  • Member
  • Posts: 4,767
Re: Could this be the holy grail ?
« Reply #613 on: October 09, 2010, 02:36:11 AM »
The following video was suggested to me by YouTube--obviously because I've watched other HIV videos there.  I know, of course, this has all been discussed here--A3G and Vif.  Has this video been shown?  Very interesting.  Sometimes it is easier for me to understand things when produced on video than reading research papers.

http://www.youtube.com/watch?v=GmQ0dg9djak&feature=grec_index

Offline veritas

  • Member
  • Posts: 1,408
Re: Could this be the holy grail ?
« Reply #614 on: October 09, 2010, 05:42:37 AM »
Pretty slides, V, but what do they mean?  :-\

Bottom line,  the first draft (rather exciting) Blueprint of a preventative/therapeutic vaccine.

 

v

Offline ElZorro

  • Member
  • Posts: 535
Re: Could this be the holy grail ?
« Reply #615 on: October 09, 2010, 12:26:48 PM »
Great video...thanks for posting, TnL

Offline veritas

  • Member
  • Posts: 1,408
Re: Could this be the holy grail ?
« Reply #616 on: November 06, 2010, 04:14:57 PM »

CHAVI expects human clinical trial using newly designed vaccine by 2012:

Consortium Assembled to Design Human Trials of Mosaic HIV Vaccine
Michelle Gailiun
Duke University Medical Center michelle.gailiun@duke.edu
October 18, 2010
An international team of scientists will design and implement the first human trial of a mosaic HIV vaccine candidate, a novel strategy that attempts to counter one of the most daunting challenges in HIV vaccine design: the virus's extensive genetic diversity.
Traditional HIV vaccines are designed to stimulate the body's immune system to recognize naturally occurring stretches of specific amino acids in the virus's proteins. In contrast, mosaic vaccines are composed of many sets of synthetic, computer-generated sequences of proteins that can prompt the immune system to respond to a wide variety of circulating HIV strains.
Such vaccines have already been studied in animals and have shown some success in enhancing the breadth of immune responses. Now, Barton Haynes, MD, director of the Duke Human Vaccine Institute and the Center for HIV/AIDS Vaccine Immunology (CHAVI), says a newly formed research coalition has begun designing an early phase safety trial to assess mosaic vaccines in humans. The trial will test the mosaic concept and could possibly lead to the next generation of HIV vaccine candidates.
Haynes, who will lead the consortium, says the group will use the NYVAC vaccinia vector (derived from the vaccine to protect against smallpox) and DNA that contain a new set of artificial computer-designed HIV genes in a phase I clinical trial that will be supported by the Bill & Melinda Gates Foundation and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Haynes says the consortium hopes to launch human trials by late 2012.
The consortium includes many of the world's leading researchers and organizations committed to finding an effective vaccine to protect against HIV infection, including the Foundation for the National Institutes of Health, the Fred Hutchinson Cancer Research Center and its NIH-funded HIV Vaccine Trials Network, the IPPOX Foundation in Switzerland, Beth Israel Deaconess Medical Center, Los Alamos National Laboratory, the NIH/NIAID Vaccine Research Center, Duke University and its Center of HIV/AIDS Vaccine Immunology, the Bill & Melinda Gates Foundation and the Division of AIDS of the National Institute of Allergy and Infectious Diseases.
Bette Korber, a senior scientist at Los Alamos National Laboratory and leader of the team that developed the mosaic genes, noted "HIV's diversity is vast, and the mosaic gene design represents a novel vaccine design to directly tackle HIV diversity in human clinical trials. Based on computational models, mosaic vaccines were predicted to perform better than natural HIV genes; experimental studies in animals that directly compared mosaic to natural vaccines supported that prediction. We are excited to test this concept in humans."
"Each member of this consortium is also a member of the Global HIV Vaccine Enterprise, and this collaboration is truly a global effort to make progress on HIV vaccine development," said Haynes.
The NYVAC vaccine is being provided by Sanofi-Pasteur, which is a collaborator in the study. The clinical development of NYVAC HIV vaccines has to date been conducted in Europe primarily through the EuroVacc Program.

v

Offline ElZorro

  • Member
  • Posts: 535
Re: Could this be the holy grail ?
« Reply #617 on: November 06, 2010, 05:37:57 PM »
V

Is this therapeutic, preventative, or both? Also, any information on how long the trial will last after it starts?

Offline veritas

  • Member
  • Posts: 1,408
Re: Could this be the holy grail ?
« Reply #618 on: November 10, 2010, 09:52:45 AM »
Zorro,

The only info I have is as posted above.

I don't think the final protocols for the trial have been developed yet. The good news is that the vaccine is a mosaic candidate that will attempt to attack the virus's extensive genetic diversity and hopefully respond to a wide variety of the (circulating ) viral strains. This approach has never been tried before. We'll have to see what develops.

They are being somewhat obtuse.

v
« Last Edit: November 10, 2010, 09:55:38 AM by veritas »

Offline veritas

  • Member
  • Posts: 1,408
Re: Could this be the holy grail ?
« Reply #619 on: November 17, 2010, 04:14:23 PM »

Why have we not heard more about Bavi's potential in HIV? Why hasn't CHAVI been more forthcoming?
(hint:$$$$$)

Connect the dots.

Perhaps some answers:

http://finance.yahoo.com/news/Peregrines-Bavituximab-iw-604776925.html?x=0&.v=1

http://files.shareholder.com/downloads/PPHM/1069248692x0x420006/ffdc0f81-aa97-4a16-97d2-3ab72e7c2d74/cbdst2010.pdf

http://www.forbes.com/2010/10/21/bioterror-vaccines-manufacturing-technology-breakthroughs-biodefense.html

CHAVI is working with PGN 635 on hiv (part of the mosaic vaccine).

v

Offline veritas

  • Member
  • Posts: 1,408
Re: Could this be the holy grail ?
« Reply #620 on: January 10, 2011, 10:35:31 AM »

BAVI tackles HEPC in a phase two trial. Therapy to last for TWELVE weeks in conjunction with ribavirin:

http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=542635

Results, hopefully, will be published in June. Could Hepc have a kinder and gentler therapy in the making?
What about other retro-viruses?

"Researchers have found that PS is exposed on the outer membrane of cells infected with HCV, HIV, influenza, herpes viruses, hemorrhagic fever viruses, respiratory syncytial virus, measles as well as other viruses. A growing body of scientific publications, including Nature Medicine and The Journal of Experimental Medicine, has highlighted data on the role of PS and Peregrine's PS-targeting therapies in infectious diseases."



Time will tell.

v

Offline stargate12

  • Member
  • Posts: 30
Re: Could this be the holy grail ?
« Reply #621 on: January 10, 2011, 12:16:56 PM »
In prior HCV clinical trials, bavituximab administered as monotherapy  also showed promising on therapy antiviral activity of up to 1.5 log viral load reduction. With limited resources Peregrine must really feel Bavi has a good shot at besting interferon's role in HCV treatment.
Fantastic.



Offline veritas

  • Member
  • Posts: 1,408
Re: Could this be the holy grail ?
« Reply #622 on: January 14, 2011, 05:45:55 AM »

http://ebdgroup.com/partneringnews/2011/01/five-companies-armed-to-fight-the-war-on-infections-disease/


"Bavituximab is being developed by Peregrine Pharmaceuticals for use in both infectious diseases and oncology. This is an anti-phosphatidylserine-targeted monoclonal antibody. As Steven King, CEO, explained, “Phosphatidylserine is tightly bound to dead and dying cells and is one of the best tumor markers we’ve found.”  The immune system down-regulates in its presence, effectively allowing cancer and infectious diseases to slip past the immune system undetected. By targeting phosphatidylserine, “Bavituximab has the potential to be a broad spectrum agent against every virus we’ve looked at,” he concluded"

Could this be why the US govt is looking so closely at Bavi?  What is CHAVI doing with anti-ps and why did they make Dr. Thorpe's lab part of their group? I wonder how bavi faired in the hepc/hiv trial?

Time will tell, but it seems to be HAPPENING!

v

Offline veritas

  • Member
  • Posts: 1,408
Re: Could this be the holy grail ?
« Reply #623 on: January 18, 2011, 05:18:28 PM »

Look who's interested in Bavituximab:

http://www.google.com/patents?q=bavituximab&lr=&sa=N&start=0

These are the one's we can see.

Who else?

v

Offline geobee

  • Member
  • Posts: 268
Re: Could this be the holy grail ?
« Reply #624 on: January 31, 2011, 11:55:56 AM »
News from Peregrine today -- here's the headline...

Peregrine Completes Patient Enrollment in Phase Ib HCV/HIV Coinfection Trial
Clinical Data From Targeted Antibody Bavituximab Expected in 2Q11

http://www.marketwire.com/press-release/Peregrine-Completes-Patient-Enrollment-in-Phase-Ib-HCV-HIV-Coinfection-Trial-NASDAQ-PPHM-1387496.htm

...and here's the text (except for the "About Peregrine" part...)

TUSTIN, CA--(Marketwire - January 31, 2011) - Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced the completion of enrollment in the company's Phase Ib dose escalation safety study of bavituximab in patients coinfected with chronic hepatitis C virus (HCV) and HIV. Previously this month, Peregrine initiated a randomized Phase II HCV trial to evaluate 12 weeks of therapy with bavituximab, a phosphatidylserine (PS)-targeting monoclonal antibody with immune-modulating potential, in combination with the antiviral drug ribavirin versus standard of care, pegylated interferon alpha 2a and ribavirin.

"Completion of enrollment in our third Phase I HCV trial is an important milestone for our bavituximab antiviral program, and sets the stage for reporting clinical data at a medical conference in the second quarter of this year while we begin to evaluate combination treatment with the antiviral agent ribavirin in a recently initiated study," said Steven W. King, president and chief executive officer of Peregrine. "Though standard treatment for chronic HCV may soon evolve with the introduction of new targeted antiviral drug candidates, immune stimulation with interferon remains a critical component of therapy. Preclinical data support the potential combination of bavituximab and ribavirin and we look forward to seeing how this combination initially compares to standard interferon and ribavirin treatment for 12 weeks in our Phase II study for patients infected with HCV."

In prior HCV clinical trials, bavituximab administered as monotherapy in single and multiple doses demonstrated a positive safety profile with no dose-limiting toxicities or serious adverse events. Bavituximab as a monotherapy also showed promising on therapy antiviral activity of up to 1.5 log viral load reduction.

Bavituximab may address a fundamental "immune evasion" mechanism exploited by many infectious pathogens. A growing body of published data from researchers worldwide shows that bavituximab's PS target, exposed on the surface of cells infected by viruses and protozoan parasites, suppresses the immune system's ability to fight disease. PS-targeting antibodies such as bavituximab bind to PS and block the immunosuppressive signals created by the target, thereby allowing the immune system to mount a robust immune response against the pathogen.

About the Phase Ib HCV Trial
Peregrine's open-label, dose escalation safety study is designed to assess the safety and of bavituximab in up to 24 patients chronically infected with HCV and HIV. Patient cohorts received ascending dose levels of bavituximab weekly for up to 8 weeks. Primary endpoints include safety and pharmacokinetics, and secondary endpoints will measure HCV and HIV RNA by PCR. For further information about Peregrine's HCV trials, please visit www.peregrinetrials.com or http://www.clinicaltrials.gov/ct2/results?term=bavituximab.

About HCV
According to the U.S. Centers for Disease Control and Prevention, an estimated 3.2 million individuals in the United States have chronic hepatitis C virus (HCV) infection. Chronic HCV infection is a serious disease that can result in long-term health problems, including liver damage, liver failure, liver cancer, or death. It is the leading cause of cirrhosis and liver cancer and the most common reason for liver transplant in the United States. Approximately 8,000 to 10,000 people die every year from HCV-related liver disease.

About Bavituximab's Antiviral Approach
Bavituximab is the first in a new class of patented antibody therapeutics that target and bind to phosphatidylserine (PS), a specific phospholipid component of cell membranes. Bavituximab helps reactivate and direct the body's immune system to destroy infected cells and virus particles that exhibit this specific phospholipid on their surface. Since their target is host-derived rather than pathogen-derived, PS-targeting antibodies have the potential for broad-spectrum antiviral activity and are also expected to be much less susceptible to the viral mutations that often lead to drug resistance.

Researchers have found that PS is exposed on the outer membrane of cells infected with HCV, HIV, influenza, herpes viruses, hemorrhagic fever viruses, respiratory syncytial virus, measles as well as other viruses. A growing body of scientific publications, including Nature Medicine and The Journal of Experimental Medicine, has highlighted data on the role of PS and Peregrine's PS-targeting therapies in infectious diseases.



Offline veritas

  • Member
  • Posts: 1,408
Re: Could this be the holy grail ?
« Reply #625 on: February 04, 2011, 06:00:37 AM »

geobee,

Thanks for posting the update.

It seems that quite a few people want a piece of Bavi. Look at this petition for herpes:


http://www.petition2congress.com/3986/view_all/

http://www.herpes-coldsores.com/messageforum/showthread.php?31113-Peregrine-Bavituximab-HSV&mode=linear

The question still remains " What is holding up the advance in infectious disease?".

DOD has been testing BAVI for a variety of infectious diseases for awhile now.

If it wasn't showing results, they would have dropped it like the plague!

Also, it's exciting to see all the potential cures being studied.  Who will reach the finish line first?

Actually, who cares, as long as the cure comes soon!

It's Happening !!

v









Offline veritas

  • Member
  • Posts: 1,408
Re: Could this be the holy grail ?
« Reply #626 on: March 31, 2011, 06:23:09 AM »
CHAVI readies "mosaic" vaccine:

http://www.lanl.gov/news/releases/consortium_to_design_human_trials_of_mosaic_hiv_vaccine_nr.html

Is anti-ps a part of this mosaic?  If you have been reading this thread, you would know the answer.

It's Happening !!

v


Offline veritas

  • Member
  • Posts: 1,408
Re: Could this be the holy grail ?
« Reply #628 on: May 06, 2011, 05:20:00 AM »

CHAVI reports -- Executive Summary- April 2011:

https://chavi.org/wysiwyg/downloads/CHAVI_Y06_Executive_Summary.pdf

v

Offline georgep77

  • Member
  • Posts: 145
Re: Could this be the holy grail ?
« Reply #629 on: March 17, 2012, 01:52:38 AM »
So what's new with this WANNABE anti HIV compound ??

   I guess it's going to be ready in 20 years lol
Come on Sangamo,  Geovax,  Bionor immuno, ...Make us happy !!!
+ 2008

Offline sensual1973

  • Member
  • Posts: 195
Re: Could this be the holy grail ?
« Reply #630 on: March 17, 2012, 01:29:52 PM »
well its the donkey and the carrot,but hope is better than no hope.
God grant me the serenity to accept the things i can not change.

Offline hoosier69

  • Member
  • Posts: 20
Re: Could this be the holy grail ?
« Reply #631 on: March 18, 2012, 05:34:23 PM »
And what happened to veritas who always kept this thread updated?

Offline ichigo_kun

  • Member
  • Posts: 49
Re: Could this be the holy grail ?
« Reply #632 on: March 18, 2012, 05:42:24 PM »
i hope he's good, or
maybe theres no update yet

Offline simpleguy

  • Member
  • Posts: 67
Re: Could this be the holy grail ?
« Reply #633 on: March 29, 2012, 04:29:58 PM »
The pipeline at Peregrine does not mention hiv, and their antiviral research is about hep. c and sadly not about hiv. Maybe they'll revive research on fighting hiv with bavituximab later?
2008 JUL: Sustiva OCT: Rayataz DEC: Kaletra • 2009 Off meds • 2011 Intelence • 2012+ Complera

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.